Kapala Julius, Jang Dan, Patel Jay, Biers Kathleen, Smieja Marek, Chernesky Max
Gamma-Dynacare Medical Laboratories, Brampton, Ont., Canada.
J Virol Methods. 2007 Jun;142(1-2):223-5. doi: 10.1016/j.jviromet.2007.01.028. Epub 2007 Feb 23.
The Digene Hybrid Capture 2 (HC2) assay for high-risk human papillomavirus (HPV) identified 92 (28.7%) infected women by testing 320 SurePath liquid-based Pap samples and a hybrid capture 2 (HC2) sampler collection. HPV positivity was predictive for high-grade lesions. A majority of women had normal cervical readings although 15.8% were HPV-positive. Half of the patients with a reading of atypical squamous cells of undetermined significance (ASCUS) (n=16) were HPV-positive.
用于检测高危型人乳头瘤病毒（HPV）的Digene杂交捕获2代（HC2）检测法，通过对320份SurePath液基巴氏样本和一个杂交捕获2代（HC2）采样收集器进行检测，确定了92名（28.7%）受感染女性。HPV阳性可预测高级别病变。尽管15.8%的女性HPV呈阳性，但大多数女性的宫颈检测结果正常。非典型鳞状细胞意义不明确（ASCUS）检测结果的患者中有一半（n = 16）HPV呈阳性。
